Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,452.18 +70.83 (+0.85%) Bitcoin USD
62,990.65 +1,970.58 (+3.23%) CMC Crypto 200
1,304.57 -53.44 (-3.93%)
Recursion Pharmaceuticals, Inc. (RXRX)
Pre-market:
| Previous close | 8.59 |
| Open | 8.60 |
| Bid | 8.62 x 100 |
| Ask | 8.67 x 600 |
| Day's range | 8.46 - 8.69 |
| 52-week range | 4.92 - 16.75 |
| Volume | |
| Avg. volume | 6,394,441 |
| Market cap | 2.052B |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.58 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
ZacksRecursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 9.30% and 3.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireRecursion Provides Business Updates and Reports First Quarter 2024 Financial Results
On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, which will support the construction of foundation models across biology, chemistry, and patient outcomesTranscriptomics technology has continued to be scaled to more than 1 million transcriptomes with a whole-genome knockout transcriptomics map to be completed in the coming quartersEntered into a multi-year a
ZacksRecursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $8.84, denoting a +0.57% change from the preceding trading day.
